Literature DB >> 6168469

The release of beta-thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery.

G Cella, O Vittadello, V Gallucci, A Girolami.   

Abstract

Cardiopulmonary bypass is extremely damaging to platelets and it causes a quantitative and qualitative alteration in their functions. We evaluated the release of two platelet-specific proteins, beta-thromboglobulin (beta TG) and platelet factor 4 (PF4), in patients who underwent extracorporeal circulation for open heart surgery. A parallel release (basal value beta TG: 119.6 ng/ml, PF4 30 ng/ml) was present for both proteins in a time dependent fashion until the end of extracorporeal circulation. High average levels were observed in patients in whom the bypass was stopped after about 1 h (beta TG 1606 ng/ml, PF4 745 ng/ml) and similarly in those in whom the bypass was stopped after about 2 h (beta TG 1540 ng/ml, PF 4754 ng/ml). No correlation was found either between the level of PF4 and the additional heparin administered after the initial standard dose (r = 0.29, P greater than 0.10) and between the level of PF4 and the amount of heparin consumed during the bypass (r = 0.05, P greater than 0.5).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168469     DOI: 10.1111/j.1365-2362.1981.tb01836.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Platelet factor 4/heparin-particle gel immunoassay (PaGIA) is a weak method for heparin-induced thrombocytopenia (HIT) evaluation of post cardio-pulmonary bypass surgery patients.

Authors:  Chezi Ganzel; Jacob Rowe; David Raveh
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

2.  The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21).

Authors:  Sanjay Khandelwal; Grace M Lee; C Garren Hester; Mortimer Poncz; Steven E McKenzie; Bruce S Sachais; Lubica Rauova; Garnett Kelsoe; Douglas B Cines; Michael Frank; Gowthami M Arepally
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

3.  PF4/heparin complexes are T cell-dependent antigens.

Authors:  Shayela Suvarna; Lubica Rauova; Emily K E McCracken; Christina M Goss; Bruce S Sachais; Steven E McKenzie; Michael P Reilly; Michael Dee Gunn; Douglas B Cines; Mortimer Poncz; Gowthami Arepally
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

Review 4.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

5.  Determinants of PF4/heparin immunogenicity.

Authors:  Shayela Suvarna; Benjamin Espinasse; Rui Qi; Rauova Lubica; Mortimer Poncz; Douglas B Cines; Mark R Wiesner; Gowthami M Arepally
Journal:  Blood       Date:  2007-09-11       Impact factor: 22.113

6.  Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.

Authors:  M Margaret Prechel; Jeanine M Walenga
Journal:  Thromb J       Date:  2013-04-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.